1. Home
  2. HIFS vs FULC Comparison

HIFS vs FULC Comparison

Compare HIFS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hingham Institution for Savings

HIFS

Hingham Institution for Savings

HOLD

Current Price

$289.55

Market Cap

600.2M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.92

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIFS
FULC
Founded
1834
2015
Country
United States
United States
Employees
97
55
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
535.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
HIFS
FULC
Price
$289.55
$7.92
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
47.0K
1.0M
Earning Date
01-16-2026
04-30-2026
Dividend Yield
0.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$209.71
$2.49
52 Week High
$338.00
$15.74

Technical Indicators

Market Signals
Indicator
HIFS
FULC
Relative Strength Index (RSI) 57.36 50.95
Support Level $286.81 $7.40
Resistance Level $290.40 $8.17
Average True Range (ATR) 9.57 0.48
MACD 2.99 0.22
Stochastic Oscillator 89.44 77.87

Price Performance

Historical Comparison
HIFS
FULC

About HIFS Hingham Institution for Savings

Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: